A fundamental question is whether T cells from CML patients under natural conditions can recognize BCR-ABL antigens, or whether through a mechanism of tumor-induced tolerance, these cells are anergized or deleted, as occurs in melanoma [25]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.